Galapagos Featured in Leading Drug Discovery Journal
News Oct 14, 2005
Galapagos NV has announced that an article presenting the Company's approach to target discovery will appear in the October 15, 2005 issue of Drug Discovery.
The paper, entitled “Biology calls the targets: combining RNAi and disease biology”, gives insight into how Galapagos applies its proprietary RNA interference technology.
Furthermore, the article explains how this biology-driven approach can be used to functionally validate drug targets for major human diseases.
“Galapagos has built extensive expertise in using RNAi to discover and validate novel drug targets in a wide range of disease areas,” said Onno van de Stolpe, CEO of Galapagos.
“Our scientists were invited to present our protein knock-down technology using adenovirus-based RNAi libraries to discover new targets in human primary cells.”
“There is particularly strong interest in RNAi in the pharmaceutical industry and we believe targets identified using our approach could improve overall success rates in the drug discovery process.”
“The confidence is underscored by the fact that our pharmaceutical partners have taken targets identified using this biology-driven strategy, forward into their internal drug discovery programs.”
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE